In the search for S1P receptor modulators with direct CNS activity, drug design studies have focused on S1P1 and S1P5 agonists, like siponimod that has shown remarkable neuroprotective effects in human and experimental MS [13,41]. Here, S1PR1 is linked to myeloid sarcoma.